Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02405533 · ClinicalTrials.gov registry record · NA
Phase II Evaluation of AHCC for the Eradication of HPV Infections
A NA study, sponsored by The University of Texas Health Science Center, Houston.
- Completed
- Registry status
- NA
- Development phase
- 50
- Enrollment target
NCT02405533 is a NA study that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 50 participants.
The verdict
NCT02405533, a NA study, has completed, sponsored by The University of Texas Health Science Center, Houston.
- COMPLETED
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
Study Summary
This is a phase II randomized, double-blind placebo-controlled, crossover trial. The primary outcome of this trial is achieving durable eradication persistent high risk HPV infection determined by HPV negative test results achieved while on active treatment with AHCC and maintained for 6 month post supplementation and 12 months post completion of AHCC treatment compared to placebo.
Interventions
- OTHER Placebo
- DIETARY_SUPPLEMENT AHCC 3 grams once a day
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2015-04 |
| Est. Completion | 2019-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02405533
The ClinicalTrials.gov registry entry for NCT02405533 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02405533 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02405533 about?
NCT02405533 is a clinical study titled "Phase II Evaluation of AHCC for the Eradication of HPV Infections". This is a phase II randomized, double-blind placebo-controlled, crossover trial. The primary outcome of this trial is achieving durable eradication persistent high risk HPV infection determined by HPV negative test results achieved while on active treatment with AHCC and maintained for 6 month post ...
What is the current status of trial NCT02405533?
This trial is currently completed. It is a NA study. The enrollment target is 50 participants. The study started on 2015-04. Estimated completion is 2019-11.
What interventions are being tested in trial NCT02405533?
The interventions under investigation include: Placebo (OTHER), AHCC 3 grams once a day (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02405533?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.